| Literature DB >> 27426299 |
Kevin D Rynearson1, Ronald N Buckle2, Keith D Barnes2, R Jason Herr2, Nicholas J Mayhew2, William D Paquette2, Samuel A Sakwa2, Phuong D Nguyen1, Graham Johnson3, Rudolph E Tanzi4, Steven L Wagner5.
Abstract
The design and construction of a series of novel aminothiazole-derived γ-secretase modulators is described. The incorporation of heterocyclic replacements of the terminal phenyl D-ring of lead compound 1 was conducted in order to align potency with favorable drug-like properties. γ-Secretase modulator 28 displayed good activity for in vitro inhibition of Aβ42, as well as substantial improvement in ADME and physicochemical properties, including aqueous solubility. Pharmacokinetic evaluation of compound 28 in mice revealed good brain penetration, as well as good clearance, half-life, and volume of distribution which collectively support the continued development of this class of compounds.Entities:
Keywords: Alzheimer’s disease; Aminothiazoles; γ-Secretase modulators
Mesh:
Substances:
Year: 2016 PMID: 27426299 DOI: 10.1016/j.bmcl.2016.07.011
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823